{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:30:40Z","timestamp":1792506640093,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2019,8,27]]},"DOI":"10.1001\/jama.2019.11642","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T11:02:14Z","timestamp":1566903734000},"page":"746","source":"Crossref","is-referenced-by-count":355,"title":["Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma"],"prefix":"10.1001","volume":"322","author":[{"given":"Julie R.","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Seattle Children\u2019s Hospital, Seattle, Washington"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Kreissman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy B.","family":"London","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Naranjo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Florida, Children\u2019s Oncology Group Statistics and Data Center, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Lerner","family":"Cohn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Hogarty","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Children\u2019s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena C.","family":"Tenney","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Florida, Children\u2019s Oncology Group Statistics and Data Center, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Haas-Kogan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dana Farber\/Brigham and Women\u2019s Cancer Center and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter John","family":"Shaw","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplant, Children's Hospital at Westmead, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Kraveka","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Memorial Sloan Kettering Cancer Center, Manhattan, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Duncan","family":"Geiger","sequence":"additional","affiliation":[{"name":"Section of Pediatric Surgery, CS Mott Children\u2019s Hospital, Michigan Medicine, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Doski","sequence":"additional","affiliation":[{"name":"Departments of Surgery and Pediatrics, UT Health San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan D.","family":"Voss","sequence":"additional","affiliation":[{"name":"Department of Radiology, Boston Children\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Maris","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Children\u2019s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Grupp","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Children\u2019s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Diller","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"joi190086r1","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma.","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"27","key":"joi190086r2","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma.","volume":"33","author":"Pinto","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"joi190086r3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41416-018-0169-8","article-title":"Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.","volume":"119","author":"Berthold","year":"2018","journal-title":"Br J Cancer"},{"issue":"10","key":"joi190086r4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","article-title":"Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.","volume":"14","author":"Kreissman","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"joi190086r5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"issue":"24","key":"joi190086r6","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1002\/cncr.v123.24","article-title":"Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children\u2019s Oncology Group early-phase trials.","volume":"123","author":"London","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"joi190086r7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/pbc.v64.1","article-title":"Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC\/SIOPEN European phase II clinical trials.","volume":"64","author":"Moreno","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"joi190086r8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/pbc.v56.4","article-title":"Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.","volume":"56","author":"Simon","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"joi190086r9","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1016\/j.ejca.2009.06.010","article-title":"Outcome of children with neuroblastoma after progression or relapse: a retrospective study of the Italian neuroblastoma registry.","volume":"45","author":"Garaventa","year":"2009","journal-title":"Eur J Cancer"},{"issue":"18","key":"joi190086r10","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1200\/JCO.2006.05.6986","article-title":"High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.","volume":"24","author":"George","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"joi190086r11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/pbc.v59.5","article-title":"Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children\u2019s Oncology Group.","volume":"59","author":"Granger","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"joi190086r12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/bmt.2012.276","article-title":"A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children\u2019s Oncology Group study ANBL00P1.","volume":"48","author":"Seif","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"33","key":"joi190086r13","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1200\/JCO.2010.34.3293","article-title":"Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children\u2019s Oncology Group study.","volume":"29","author":"Park","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"joi190086r14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.pcl.2014.09.015","article-title":"Neuroblastoma: paradigm for precision medicine.","volume":"62","author":"Irwin","year":"2015","journal-title":"Pediatr Clin North Am"},{"issue":"5","key":"joi190086r15","first-page":"240","article-title":"The International Neuroblastoma Pathology Classification.","volume":"95","author":"Shimada","year":"2003","journal-title":"Pathologica"},{"issue":"16","key":"joi190086r16","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid.","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"joi190086r17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3389\/fimmu.2018.01355","article-title":"A comprehensive safety trial of chimeric antibody 14.18 with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children\u2019s Oncology Group Study ANBL0931.","volume":"9","author":"Ozkaynak","year":"2018","journal-title":"Front Immunol"},{"issue":"14","key":"joi190086r18","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"issue":"27","key":"joi190086r19","doi-asserted-by":"publisher","first-page":"6466","DOI":"10.1200\/JCO.2005.05.582","article-title":"Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.","volume":"23","author":"George","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"joi190086r20","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1002\/pbc.v61.11","article-title":"Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.","volume":"61","author":"Meany","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"joi190086r21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1200\/JCO.2000.18.6.1260","article-title":"Biologic factors determine prognosis in infants with stage IV neuroblastoma: a prospective Children\u2019s Cancer Group study.","volume":"18","author":"Schmidt","year":"2000","journal-title":"J Clin Oncol"},{"key":"joi190086r22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation for incomplete evaluations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"joi190086r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II: analysis and examples.","volume":"35","author":"Peto","year":"1977","journal-title":"Br J Cancer"},{"issue":"2","key":"joi190086r24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The International Neuroblastoma Risk Group (INRG) Classification system: an INRG task force report.","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"joi190086r25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.","volume":"11","author":"Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"joi190086r27","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/(ISSN)1545-5017","article-title":"High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.","volume":"44","author":"Pritchard","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"joi190086r28","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1200\/JCO.2006.09.2148","article-title":"Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.","volume":"25","author":"Lorch","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"joi190086r29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma.","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"joi190086r30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/bmt.2017.166","article-title":"Marrow-ablative chemotherapy followed by tandem autologous hematopoietic cell transplantation in pediatric patients with malignant brain tumors.","volume":"52","author":"Guerra","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"joi190086r31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000489135","article-title":"The role of salvage high-dose chemotherapy in relapsed male germ cell tumors.","volume":"41","author":"Oing","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"2","key":"joi190086r32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3324\/haematol.2017.174573","article-title":"From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives.","volume":"103","author":"Gay","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"joi190086r33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/bmt.2013.218","article-title":"Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems.","volume":"49","author":"Cohen","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"joi190086r34","doi-asserted-by":"publisher","first-page":"e1229","DOI":"10.1542\/peds.2007-0178","article-title":"Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children\u2019s Oncology Group.","volume":"120","author":"Gurney","year":"2007","journal-title":"Pediatrics"},{"issue":"7","key":"joi190086r35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/pbc.24452","article-title":"Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience.","volume":"60","author":"Moreno","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"joi190086r36","doi-asserted-by":"publisher","first-page":"e27372","DOI":"10.1002\/pbc.27372","article-title":"Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.","volume":"65","author":"Desai","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"joi190086r37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/bjc.2015.12","article-title":"Phase I\/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.","volume":"112","author":"DuBois","year":"2015","journal-title":"Br J Cancer"},{"issue":"12","key":"joi190086r38","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1158\/1078-0432.CCR-14-3240","article-title":"Phase I study of vorinostat as a radiation sensitizer with 131i-metaiodobenzylguanidine (131I-MIBG) for patients with relapsed or refractory neuroblastoma.","volume":"21","author":"DuBois","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"joi190086r39","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/1078-0432.CCR-13-1012","article-title":"Phase I trial of a bivalent gangliosides vaccine in combination with \u00df-glucan for high-risk neuroblastoma in second or later remission.","volume":"20","author":"Kushner","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"joi190086r40","doi-asserted-by":"publisher","first-page":"e1016704","DOI":"10.1080\/2162402X.2015.1016704","article-title":"Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study.","volume":"4","author":"Kushner","year":"2015","journal-title":"Oncoimmunology"},{"key":"joi190086r41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejca.2016.12.013","article-title":"Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.","volume":"76","author":"Kraal","year":"2017","journal-title":"Eur J Cancer"},{"key":"joi190086r26","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events: Version 4.0. Washington, DC: US Department of Health and Human Services; 2009. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf."}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/article-pdf\/322\/8\/746\/17861216\/jama_park_2019_oi_190086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T15:05:01Z","timestamp":1567177501000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2748795"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,8,27]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,27]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2019.11642","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,27]]}}}